These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9636447)

  • 21. Antibody induction therapy in pancreas transplantation.
    Gruessner RW
    Transplant Proc; 1998 Jun; 30(4):1556-9. PubMed ID: 9636632
    [No Abstract]   [Full Text] [Related]  

  • 22. Biological immunosuppressants: the way to clinical transplantation tolerance.
    Chatenoud L
    Transplant Proc; 1997; 29(1-2):51-5. PubMed ID: 9123108
    [No Abstract]   [Full Text] [Related]  

  • 23. [Immunosuppression after heart and lung transplantation].
    Wendler O; Schäfers HJ
    Med Klin (Munich); 1997 Dec; 92 Suppl 5():3-7. PubMed ID: 19479389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avenues for acquired immune tolerance.
    Wood KJ; Morris PJ
    Semin Thorac Cardiovasc Surg; 1990 Apr; 2(2):189-97. PubMed ID: 2081227
    [No Abstract]   [Full Text] [Related]  

  • 25. Acute cardiac ongoing rejection: comparison between different strategies.
    Forni A; Faggian G; Luciani GB; Lamascese N; Mazzucco A
    Transplant Proc; 2001 May; 33(3):2395-7. PubMed ID: 11377573
    [No Abstract]   [Full Text] [Related]  

  • 26. New usage paradigms in antibody therapy: safety of the new agents.
    Pescovitz MD
    Transplant Proc; 1999; 31(1-2):1201-2. PubMed ID: 10083537
    [No Abstract]   [Full Text] [Related]  

  • 27. Relative clinical impact of cyclosporine vs steroid induction therapy on renal function and allograft rejection in heart transplant recipients.
    Hanrahan JS; Ibrahim H; Tolman D; Kirchberg D; Salter D; Guerraty A; Mohanty PK
    Transplant Proc; 1996 Aug; 28(4):2107-8. PubMed ID: 8769168
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of cyclosporine dose on long-term outcome after heart transplantation.
    Valantine H; Hunt S; Gamberg P; Miller J; Luikart H
    Transplant Proc; 1994 Oct; 26(5):2710-2. PubMed ID: 7940848
    [No Abstract]   [Full Text] [Related]  

  • 29. Induction therapies with polyclonal antithymocyte globulins or monoclonal antibodies.
    Charpentier B; Hiesse C; Marchand S; Boubenider S; Ammor M; Kechrid C; Benoit G; Durrbach A
    Transplant Proc; 2000 Mar; 32(2):367. PubMed ID: 10715442
    [No Abstract]   [Full Text] [Related]  

  • 30. Optimal timing for surveillance endomyocardial biopsies in heart transplant patients receiving antithymocyte globulin induction.
    Cantarovich M; de Gruchy S; Forbes C; Marpole D; Elstein E; Magnan C; de Varennes B
    Transplant Proc; 1999; 31(1-2):79. PubMed ID: 10083015
    [No Abstract]   [Full Text] [Related]  

  • 31. Unique antithymocyte serum versus OKT3 for induction immunotherapy after heart transplantation.
    Frist WH; Merrill WH; Eastburn TE; Atkinson JB; Stewart JR; Hammon JW; Bender JW
    J Heart Transplant; 1990; 9(5):489-94. PubMed ID: 2121921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
    Laske A; Gallino A; Schneider J; Bauer EP; Carrel T; Pasic M; von Segesser LK; Turina MI
    J Heart Lung Transplant; 1992; 11(3 Pt 1):557-63. PubMed ID: 1610864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological reagents for immunosuppressants.
    Soulillou JP
    Transplant Proc; 1995 Feb; 27(1):106-8. PubMed ID: 7878803
    [No Abstract]   [Full Text] [Related]  

  • 34. Antibody therapy in steroid-resistant rejection.
    Waiser J; Budde K; Schreiber M; Böhler T; Löbermann LA; Neumayer HH
    Transplant Proc; 1998 Aug; 30(5):1778-9. PubMed ID: 9723279
    [No Abstract]   [Full Text] [Related]  

  • 35. Recipient selection algorithm for immunosuppression in cardiac transplantation: OKT3 vs triple therapy alone.
    Rabinov M; Benson E; Cochrane A; Williams T; Bergin P; Federman J; Esmore D
    Transplant Proc; 1992 Feb; 24(1):167-8. PubMed ID: 1539226
    [No Abstract]   [Full Text] [Related]  

  • 36. Adjuncts to triple-drug therapy after cardiac transplantation: a comparison of Nashville rabbit antithymocyte serum to OKT3.
    Aziz S; Kruse AP; Roby PV; Allen MD; Khan K; Fishbein D
    Transplant Proc; 1994 Oct; 26(5):2721-3. PubMed ID: 7940852
    [No Abstract]   [Full Text] [Related]  

  • 37. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The Collaborative Transplant Study.
    Opelz G
    Transplant Proc; 1997; 29(1-2):73-6. PubMed ID: 9123162
    [No Abstract]   [Full Text] [Related]  

  • 38. Preoperative prophylactic OKT3 vs RATG. A randomized clinical study in heart transplant patients.
    Ippoliti G; Negri M; Abelli P; Rovati B; Di Franco L; Grossi P; Minoli L; Ascari E; Viganó M
    Transplant Proc; 1991 Aug; 23(4):2272-4. PubMed ID: 1908155
    [No Abstract]   [Full Text] [Related]  

  • 39. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
    Flaman F; Zieroth S; Rao V; Ross H; Delgado DH
    J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute pulmonary insufficiency due to OKT3 therapy.
    Büsing M; Mellert J; Greger B; Hopt UT
    Transplant Proc; 1990 Aug; 22(4):1779-81. PubMed ID: 2117808
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.